Evaluating and discerning talent at the quarterback position in the NFL is long and arduous, and not surprisingly, as nailing the player you place at the helm can often make the difference between a ...
The TRITON study is evaluating tremelimumab/durvalumab/chemotherapy vs pembrolizumab/chemotherapy in non–small lung cancer (NSCLC) with STK11 and/or KEAP1 and/or ...
SAINT-PREX, Switzerland--(BUSINESS WIRE)--Ferring Pharmaceuticals today announces results from the OPTIMISE study showing the first real-world evidence of the effectiveness of a treat-to-target (T2T) ...
Routine vaccines have prevented the deaths of about 154 million children around the world over the past 50 years, a new study shows, but efforts have been slowing recently, allowing for the growth of ...
BofA Securities has upgraded Fulcrum Therapeutics (NASDAQ:FULC) ahead of the company’s phase 3 losmapimod readout, expected by the end of October for Facioscapulohumeral muscular dystrophy (FSHD).
Surmodics (SRDX) announced that results from an analysis of 160 real-world patients with symptomatic infrainguinal limb ischemia from its PROWL ...
Please provide your email address to receive an email when new articles are posted on . Rezpegaldesleukin is a first-in-class interleukin-2 receptor agonist that proliferates and activates regulatory ...
A study from St. Jude Children's Research Hospital uncovered an alternative binding pocket within nuclear receptors, ...
An all-equity portfolio, with a focus on international stocks, could be the key to maximizing retirement wealth, research suggests. Forget 60/40. Goodbye, target-date funds. So long, bonds. An all ...
Russell W. Jenkins, MD, PhD, a physician investigator in the Krantz Family Center for Cancer Research at the Mass General Cancer Center and an assistant professor of Medicine at Harvard Medical School ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback